labedipinedilol A

Known as: labedipinedilol-A 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2013
01220042013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
OBJECTIVE Inflammation is an important molecular basis of atherosclerosis. Recent studies have shown that dihydropyridine calcium… (More)
Is this relevant?
2011
2011
OBJECTIVE Labedipinedilol-A, a novel calcium antagonist, has been previously demonstrated to have pleiotropic protective effects… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 6
Is this relevant?
2009
2009
In this research, we conducted an in vitro analysis to evaluate the prostate cancer cells response to labedipinedilol-A in order… (More)
Is this relevant?
2009
2009
Labedipinedilol-A, a novel calcium channel blocker with alpha/beta-adrenoceptor blockade properties, inhibits L-type calcium… (More)
Is this relevant?
2006
2006
The effects of labedipinedilol-A, a novel dihydropyridine-type calcium channel blocker with alpha-/beta-adrenoceptor blocking… (More)
Is this relevant?
2005
2005
Intravenous and oral labedipinedilol-C showed a dose-dependent long-lasting hypotension and a decrease of heart rate in… (More)
Is this relevant?
2005
2005
Labedipinedilol-A, a novel dihydropyridine-type calcium antagonist, has been shown to induce hypotension and vasorelaxation. The… (More)
Is this relevant?
2004
2004
Labedipinedilol-A is a novel 1, 4-dihydropyridine type calcium antagonist with alpha-receptor blocking activity. This study… (More)
Is this relevant?